This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
I
UK-EPCOR-260211 | June 2026
UK-EPCOR-260211 | June 2026
Previous
Next
Downloadable Resources
Tepkinly dosing and administration guide
A digital guide to dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly, along with important safety information.
Tepkinly patient information booklet
A booklet for you to download and pass onto your patients who have been prescribed Tepkinly. It contains information that can be referred to throughout treatment, including understanding the Tepkinly treatment routine and possible side effects. This is for use in conjunction with the patient information leaflet.
4–year data
Using Tepkinly
Tepkinly Preparation and Administration: The syringe method
An overview of the syringe method for preparing Tepkinly, including the dilution of step-up doses (0.16 mg and 0.8 mg) and the preparation of the full 48 mg dose for subcutaneous administration. Watch this video for guidance on handling, storage, and preparation using the syringe technique.
Tepkinly Mode of Action animation
The Tepkinly mechanism of action is explained in this video which shows how by binding simultaneously to CD3 on T cells and CD20 on B cells, epcoritamab forms an immune synapse – inducing cytokine release and T-cell–mediated killing of malignant CD20-expressing cells.1
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Abbreviations
CNS=clinical nurse specialist; DLBCL=diffuse large B-cell lymphoma; R/R=relapsed/refractory.
References
- Tepkinly Summary of Product Characteristics.
UK-EPCOR-260179. Date of prepatation: June 2026.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
